MYGN
$4.49
Revenue | $205.7Mn |
Net Profits | $-27.4Mn |
Net Profit Margins | -13.32% |
Myriad Genetics Inc.’s revenue fell -3.56% since last year same period to $205.7Mn in the Q3 2025. On a quarterly growth basis, Myriad Genetics Inc. has generated -3.47% fall in its revenue since last 3-months.
Myriad Genetics Inc.’s net profit fell -23.98% since last year same period to $-27.4Mn in the Q3 2025. On a quarterly growth basis, Myriad Genetics Inc. has generated 91.71% jump in its net profits since last 3-months.
Myriad Genetics Inc.’s net profit margin fell -28.56% since last year same period to -13.32% in the Q3 2025. On a quarterly growth basis, Myriad Genetics Inc. has generated 91.41% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0 |
EPS Estimate Current Year | -0 |
Myriad Genetics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0 - a 88.95% jump from last quarter’s estimates.
Myriad Genetics Inc.’s earning per share (EPS) estimates for the current year stand at -0.
Earning Per Share (EPS) | 0 |
Myriad Genetics Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Myriad Genetics Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-04-30 | -0 | 0 | 100% |